Literature DB >> 33248996

Transapical Transcatheter Valve Replacement Using J-Valve for Aortic Valve Diseases.

Yunxing Xue1, Qing Zhou1, Shuchun Li1, Jie Li2, Dan Mu3, Xuan Luo1, Chang Liu1, Can Xu1, Dongjin Wang4.   

Abstract

BACKGROUND: The J-Valve system (Jie ChengMedical Technologies, Suzhou, China) is designed specifically for transapical transcatheter aortic valve replacement and has three U-shaped graspers. With the unique structure, the J-Valve is suitable for both aortic stenosis and aortic regurgitation. We used the J-Valve system for patients with aortic valve diseases and observed favorable results.
METHODS: From January 2018 to August 2019, 23 patients underwent transapical transcatheter valve replacement using the J-Valve system. High-risk patients with diseased peripheral vessels (small diameter, heavily calcified, and tortuous arteries), pure aortic regurgitation, and complex prosthetic valve-in-valve cases were enrolled. Ten patients mainly had aortic stenosis, 11 patients had pure aortic regurgitation, and 2 patients had valve-in-valve aortic valve position. The Society of Thoracic Surgeons and European System for Cardiac Operative Risk Evaluation average preoperative scores were 8.9% and 8.7%, respectively.
RESULTS: The technique success rate was 91.3% (21 of 23; 1 patient was referred for open surgery and 1 patient received intraoperative valve-in-valve), and 1 patient died of cardiogenic shock after the procedure (mortality 4.3%, 1 of 22). One patient had stroke postoperatively and recovered well; no cases needed to undergo permanent pacemaker implantation. During the follow-up period, 1 patient died of acute heart attack. No moderate or severe paravalvular leakage was found.
CONCLUSIONS: Transcatheter aortic valve replacement surgery with the J-Valve system is effective, even when it is traumatic and requires the transapical route. The applicability of the J-Valve system in pure aortic regurgitation patients is the advantage of this system.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Year:  2020        PMID: 33248996     DOI: 10.1016/j.athoracsur.2020.10.030

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  2 in total

1.  Omniparticle Contrast Agent for Multimodal Imaging: Synthesis and Characterization in an Animal Model.

Authors:  Neil Robertson; Lorenzo Sempere; Elizabeth Kenyon; Christiane Mallet; Kylie Smith; Jeremy Hix; Alan Halim; Jinda Fan; Anna Moore
Journal:  Mol Imaging Biol       Date:  2022-09-07       Impact factor: 3.484

2.  30-Day Outcomes after Surgical or Transapical Aortic Valve Replacement in Symptomatic Aortic Regurgitation.

Authors:  Minjian Kong; Ze Hong; Xianbao Liu; Xian Zhu; Jianan Wang; Aiqiang Dong
Journal:  J Cardiovasc Dev Dis       Date:  2022-07-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.